Top 50 Gene Edited Seed in Europe

Inari is a seed design and biotechnology company focused on developing genetically optimized seeds that enhance agricultural productivity while promoting biodiversity. Their approach addresses the need for sustainable food production systems by creating seeds that require fewer resources and reduce environmental impact.

Tropic Biosciences develops high-performing tropical crop varieties using CRISPR gene editing and RNA interference to enhance disease resistance and reduce pesticide reliance. Their technology addresses the challenges of climate change and food security by improving the yield and resilience of staple crops like bananas, coffee, and rice.

Hudson River Biotechnology utilizes CRISPR-based gene editing to enhance specific traits in plants, improving crop quality and yield while minimizing agricultural inputs. Their targeted delivery systems for agrochemicals further reduce environmental impact, addressing the inefficiencies in traditional farming practices.

Phytoform Labs utilizes artificial intelligence and genome editing to enhance plant DNA diversity, creating resilient and sustainable crops that can withstand climate change. Their technology accelerates the development of diverse crop traits, addressing the urgent need for future-proof agricultural solutions.

Signia Therapeutics is a French startup focused on developing targeted therapies for genetic disorders using advanced gene editing techniques. The company aims to provide precise treatment options that address the underlying genetic causes of these conditions, improving patient outcomes and quality of life.

The startup develops a gene editing and genome engineering platform that creates human-compatible organ tissue cells for solid organ and therapeutic cell transplantation. This technology aims to improve outcomes for patients with life-threatening diseases by enabling successful kidney and islet cell transplants.

Develops proprietary genomic editors that target the root causes of genetic diseases by selecting optimal editing tools based on disease-specific pathology. This approach enables the discovery and development of potentially curative genomic medicines, with a focus on liver and central nervous system disorders.

Seamless Therapeutics develops disease-modifying gene editing candidates using programmable recombinase technology. This approach enables precise, large DNA edits within the genome without introducing unintended mutations. The company aims to expand the therapeutic potential of gene editing to treat severe genetic diseases.

Plantik Biosciences develops plant engineering workflows that leverage genomic data to unlock underexplored genetic variation for crop resilience. The company focuses initially on creating thermotolerant plants to mitigate the impact of increasing heat stress on agriculture. This biotechnology approach aims to deliver climate-resilient crops for improved food security.

Beam Therapeutics develops precision genetic medicines using base editing technology to enable targeted modifications of DNA sequences. This approach addresses the limitations of traditional gene editing methods, offering potential treatments for genetic disorders with improved accuracy and reduced off-target effects.

Prime Medicine utilizes Prime Editing, a precise gene editing technology that enables the targeted replacement of faulty DNA sequences without causing double-strand breaks. This approach aims to directly correct genetic mutations responsible for debilitating diseases, potentially offering long-lasting therapeutic benefits.

The company develops genome editing-based therapies for genetic disorders, oncology, and organ transplants. Their technology enables precise genetic recombination to create off-the-shelf treatments for previously incurable diseases.

Faze Medicines is a biotechnology company focused on developing targeted therapies using advanced gene editing techniques to address genetic disorders. Their approach aims to enhance treatment precision and improve patient outcomes by directly modifying disease-causing genes.

Tessera Therapeutics is pioneering Gene Writing™, a genome engineering technology that enables precise alterations to the human genome to treat genetic diseases at their source. This platform addresses the need for permanent and potentially curative therapies by delivering therapeutic genetic modifications directly to targeted tissues without the use of viral vectors.

SparingVision is a clinical-stage biotechnology company developing mutation-independent genomic therapies for Inherited Retinal Diseases (IRDs), including Retinitis Pigmentosa, which affects millions globally. Their approach utilizes advanced gene therapy and genome editing techniques to provide treatment options for patients regardless of the specific genetic mutations causing their conditions.

This company develops genomic technology focused on improving the safety and characterization of gene editing tools for cell and gene therapies. Their INDUCE-seq platform enables developers to accurately detect on- and off-target edits associated with gene editing systems like CRISPR. This technology supports the standardization and acceleration of safer gene-edited therapeutic development.

Twelve Bio develops CRISPR-Cas12a diagnostic technology that enables precise detection and modification of DNA sequences. This technology addresses the need for accurate genetic diagnostics and targeted gene editing to treat genetic disorders and diseases.

Nvelop Therapeutics develops programmable, non-viral delivery vehicles for efficient in vivo gene editing, targeting specific tissues and cell types with a range of therapeutic cargoes. The company addresses the challenge of safe and effective delivery technologies, expanding the potential for precision medicine in previously undruggable diseases.

The startup develops biomimetic peptides, biofertilizers, and bioherbicides that manipulate plant genetics to enhance agricultural yields. By utilizing micro-peptides and their influence on plant phenotypes, the company enables farmers to control germination rates, improve disease resistance, and accelerate flowering.

AIRNA is developing RNA editing therapies to treat rare and common diseases by precisely modifying RNA sequences to correct genetic mutations. This approach aims to enhance patient health outcomes by targeting the underlying causes of genetic disorders.

Invaio Sciences develops precision biotechnologies, including its proprietary Trecise™ application technology, to create biological crop protection solutions that reduce reliance on traditional chemical pesticides. The company addresses crop yield loss due to pests and diseases by providing farmers with sustainable alternatives that enhance environmental health and biodiversity.

Anthology generates diverse, designer genomes by combining genetic parts across species boundaries to create novel biological capabilities. This technology enables the scalable and efficient production of functional proteins for human nutrition, improved animal health solutions, and carbon-neutral bioproduction from waste feedstocks. The resulting designer genomes maximize the practical impact of biology in addressing major global challenges.

Camena Bioscience develops the gSynth® platform, a TdT-free enzymatic DNA synthesis technology that enables the high-throughput production of synthetic genes of any sequence, length, and complexity. This technology addresses the limitations of traditional DNA synthesis methods, which struggle to produce long, accurate synthetic DNA at scale, thereby facilitating advancements in personalized mRNA vaccines, cell and gene therapies, and CRISPR applications.

Evonetix is developing a desktop platform that synthesizes gene-length DNA with high accuracy and scalability using a novel approach to DNA synthesis. This technology provides researchers with rapid access to precise genetic material, addressing the limitations of current gene synthesis methods that hinder innovation in healthcare and biotechnology.

Dyno Therapeutics utilizes artificial intelligence to design novel adeno-associated virus (AAV) vectors for gene therapy, enhancing delivery efficiency for a wide range of human diseases. The company aims to increase patient access to effective treatments while significantly reducing the cost of in vivo gene delivery.

The startup develops gene therapy treatments for orphan diseases using a modified adeno-associated virus (AAV) vector to deliver a functional version of the ATP7B gene into liver cells. This approach targets inherited disorders such as Wilson disease, Progressive Familial Intrahepatic Cholestasis, and Citrullinemia Type I, providing a potential therapeutic solution for patients with these conditions.

TQx has developed a highly automated, extra-corporeal gene therapy platform that enables the rapid production of genetically modified immune cells, such as CAR-T cells, directly at the patient's side. This approach eliminates the lengthy and costly centralized manufacturing process, making autologous cell therapies more accessible for treating rare autoimmune diseases and cancers.

Chroma Medicine is developing epigenetic editing technologies that modify chromatin structure to precisely regulate gene expression without altering the DNA sequence. This approach aims to create durable genomic therapies for diseases that currently lack effective treatments.

Seedsight develops a platform that utilizes optical sensing, blockchain, and AI to create a digital database of seed and grain signatures, validated through biomolecular analyses. This technology enables grain traders and processors to enhance procurement efficiency, reduce screening costs by 8%, and decrease procurement time by up to 89%, while ensuring traceability and quality standards.

Genespire develops immune-shielded lentiviral vectors to deliver gene therapies for children with genetic diseases. The company aims to provide these patients with effective treatment options that can significantly improve their quality of life.

Ring Therapeutics utilizes its Anellogy™ platform to engineer anellovirus-based gene therapies that can effectively target specific cells and tissues while evading the immune system. This approach addresses the need for safe and versatile delivery mechanisms for diverse therapeutic modalities in patients with significant medical needs.

Ikarovec is a pre-clinical gene therapy company developing targeted treatments for diabetic macular edema and other common eye diseases through gene transfer techniques that introduce therapeutic DNA into ocular cells. This approach aims to provide long-lasting benefits with a single injection, reducing the need for frequent treatments and addressing the risk of vision loss.

VeonGen develops next-generation gene therapies primarily for ophthalmic diseases with high unmet medical need. The company utilizes proprietary vector platforms, including vgAAV and vgRNA REVeRT, to overcome limitations of traditional AAV therapies for superior delivery and large gene expression. These platforms enable less invasive administration routes and the modulation of multiple genes for therapeutic effect.

DNA-LM develops a universal language model pre-trained on diverse DNA sequences to process entire genomes. This model aims to accurately predict phenotypic traits across molecular and organism scales, reducing the need for extensive labeled data.

The startup utilizes engineered microbes to enhance nutrient uptake and increase crop resilience against pests, improving soil health and agricultural productivity. This technology addresses soil degradation and reduces reliance on chemical fertilizers in conventional farming practices.

Protealis develops and supplies high-performance soybean varieties optimized for European cultivation and protein production. The company focuses on data-backed breeding technology to deliver superior yield and protein content for the feed and food supply chain. They aim to strengthen regional legume production through advanced agricultural science and farmer collaboration.

Spur Therapeutics is developing targeted gene therapies that precisely modulate gene expression to halt the progression of chronic conditions such as Gaucher disease, Parkinson's, and certain cardiovascular diseases. By delivering a single dose of genetic medicine, the company aims to transform the treatment landscape for debilitating illnesses, improving patient outcomes and quality of life.

Robigo engineers microbes to create effective and environmentally friendly crop protectants, addressing the significant crop losses of 20-40% due to diseases despite the use of over 6 billion pounds of pesticides annually. By enhancing soil health and increasing farm productivity, Robigo's biomanufacturing solutions promote sustainable agricultural practices.

Seed Health leverages computational biology and ultra-deep sequencing to analyze host-microbe interactions, enabling the development of prebiotics, probiotics, and synbiotics that enhance gut health and overall well-being. The company addresses the lack of effective probiotic solutions by commercializing scientifically validated products that optimize the human microbiome across various life stages.

Flash Therapeutics specializes in the development of gene and cell-based therapies using its proprietary lentiviral vector platform, which enables stable and long-term DNA transfer. The company provides reliable viral vector manufacturing services to meet the growing demand for effective treatments in cell and gene therapy.

Comet Therapeutics develops targeted therapies for orphan neurological disorders using advanced gene therapy techniques to address the lack of effective treatments for these rare conditions. Their approach aims to restore neurological function and improve quality of life for patients suffering from debilitating diseases.

STRM.BIO utilizes extracellular vesicles to deliver gene therapy, enhancing the efficiency and safety of treatment for patients with rare diseases. This approach aims to simplify the administration of gene therapies, making them more practical and accessible for global patient populations.

Alia Therapeutics is developing next-generation gene-editing therapies that utilize precise genome editing techniques to target and correct mutations responsible for rare genetic diseases. By focusing on the efficacy and durability of these treatments, the company aims to provide long-lasting cures that address the root causes of genetic disorders.

This startup develops DNA technology tailored for synthetic biology applications, providing high-throughput libraries and custom DNA sequences for genome construction and data storage. Their services enable researchers and companies to efficiently create and manipulate DNA without facing economic or time constraints.

The startup develops microbial products that enable farmers to cultivate healthier crops while minimizing the reliance on pesticides, antibiotics, and synthetic fertilizers. By replacing harmful agrochemicals, the company promotes sustainable agricultural practices that reduce environmental emissions and enhance food safety.

Wild Bioscience develops resilient crop varieties using genetic traits from wild plants to enhance agricultural productivity and carbon absorption. Their solutions directly address the challenges of climate change and food security by improving yield while reducing the environmental impact of farming practices.

Eligo offers a CRISPR‑based platform that delivers non‑replicative gene‑editing payloads directly to specific gut bacteria, enabling precise in‑situ modification of microbial genomes with near‑100 % efficiency. The technology can knock out disease‑associated genes, restore beneficial functions, or add therapeutic capabilities while preserving the overall microbiome, supporting both drug development and microbiome research.

This biotechnology company applies molecular and plant biology, along with RNA expertise, to develop solutions for the food and agriculture sectors. Their focus is on improving agricultural systems through scientific advancements.

Myrtelle is a gene therapy company conducting clinical trials that utilize targeted gene delivery techniques to treat rare monogenic disorders. The company focuses on providing therapeutic options for patients with genetic conditions that currently have no effective treatments available.

This biotechnology company leverages AI to predict complex agricultural traits, accelerating the development of high-yielding and climate-resilient crop varieties and animal breeds. Their platform enables breeders to quickly and cost-effectively predict traits across their livestock or germplasm, optimizing agricultural output.